Review



pfsk1 cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    ATCC pfsk1 cells
    (a) IgG binding on <t>PFSK1</t> cells from CSF of MS donors compared with non-inflammatory controls ( p = 0.008, Mann–Whitney test) using an anti-IgG antibody. Each dot corresponds to the binding of IgG on PFSK1 (ratio of geometric mean of the florescence intensity – GMFI – of cells incubated with the sample to cells incubated only with secondary antibody) from each CSF sample. (b) IgG binding on PFSK1 cells in natalizumab treated compared with untreated patients; results from two independently tested cohorts are pooled and expressed as the number of standard deviations by which each sample is above or below the mean value of the control samples ( p < 0.0001, Mann–Whitney test). Each dot corresponds to one sample. (c) Natalizumab detection in CSF from treated patients compared with untreated patients ( p < 0.0015, Mann–Whitney test) using an anti-IgG 4 antibody. Each dot corresponds to the binding of IgG 4 on PFSK1 (ratio of geometric mean of the florescence intensity – GMFI – of cells incubated with the sample to cells incubated only with secondary antibody) from each serum sample. (d) Natalizumab detection in serum from treated patients compared with untreated patients ( p < 0.0018, Mann–Whitney test) using an anti-IgG 4 antibody. Each dot corresponds to the binding of IgG 4 on PFSK1 (ratio of GMFI of cells incubated with the sample to cells incubated only with secondary antibody) from each serum sample.
    Pfsk1 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 97 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pfsk1+cells/pmc09896084-41-0-8?v=ATCC
    Average 94 stars, based on 97 article reviews
    pfsk1 cells - by Bioz Stars, 2026-08
    94/100 stars

    Images

    1) Product Images from "Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis"

    Article Title: Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis

    Journal: Therapeutic Advances in Neurological Disorders

    doi: 10.1177/17562864221150040

    (a) IgG binding on PFSK1 cells from CSF of MS donors compared with non-inflammatory controls ( p = 0.008, Mann–Whitney test) using an anti-IgG antibody. Each dot corresponds to the binding of IgG on PFSK1 (ratio of geometric mean of the florescence intensity – GMFI – of cells incubated with the sample to cells incubated only with secondary antibody) from each CSF sample. (b) IgG binding on PFSK1 cells in natalizumab treated compared with untreated patients; results from two independently tested cohorts are pooled and expressed as the number of standard deviations by which each sample is above or below the mean value of the control samples ( p < 0.0001, Mann–Whitney test). Each dot corresponds to one sample. (c) Natalizumab detection in CSF from treated patients compared with untreated patients ( p < 0.0015, Mann–Whitney test) using an anti-IgG 4 antibody. Each dot corresponds to the binding of IgG 4 on PFSK1 (ratio of geometric mean of the florescence intensity – GMFI – of cells incubated with the sample to cells incubated only with secondary antibody) from each serum sample. (d) Natalizumab detection in serum from treated patients compared with untreated patients ( p < 0.0018, Mann–Whitney test) using an anti-IgG 4 antibody. Each dot corresponds to the binding of IgG 4 on PFSK1 (ratio of GMFI of cells incubated with the sample to cells incubated only with secondary antibody) from each serum sample.
    Figure Legend Snippet: (a) IgG binding on PFSK1 cells from CSF of MS donors compared with non-inflammatory controls ( p = 0.008, Mann–Whitney test) using an anti-IgG antibody. Each dot corresponds to the binding of IgG on PFSK1 (ratio of geometric mean of the florescence intensity – GMFI – of cells incubated with the sample to cells incubated only with secondary antibody) from each CSF sample. (b) IgG binding on PFSK1 cells in natalizumab treated compared with untreated patients; results from two independently tested cohorts are pooled and expressed as the number of standard deviations by which each sample is above or below the mean value of the control samples ( p < 0.0001, Mann–Whitney test). Each dot corresponds to one sample. (c) Natalizumab detection in CSF from treated patients compared with untreated patients ( p < 0.0015, Mann–Whitney test) using an anti-IgG 4 antibody. Each dot corresponds to the binding of IgG 4 on PFSK1 (ratio of geometric mean of the florescence intensity – GMFI – of cells incubated with the sample to cells incubated only with secondary antibody) from each serum sample. (d) Natalizumab detection in serum from treated patients compared with untreated patients ( p < 0.0018, Mann–Whitney test) using an anti-IgG 4 antibody. Each dot corresponds to the binding of IgG 4 on PFSK1 (ratio of GMFI of cells incubated with the sample to cells incubated only with secondary antibody) from each serum sample.

    Techniques Used: Binding Assay, MANN-WHITNEY, Incubation, Control

    (a) Natalizumab binding on VLA-4 expressing cells (PFSK1) compared with non-expressing cells (HEK293/T17) by flow cytometry using an FITC-conjugated secondary anti-IgG 4 . (b) Effect of natalizumab blocking antibody HCA250 on natalizumab and milk (T2) IgG 4 binding to PFSK1 cells. Serum was used at 1:40 dilution. Each column corresponds to average binding of IgG 4 on PFSK1 (geometric mean of the florescence intensity – GMFI – of cells incubated with the sample) from three replicates. Error bars are standard error. (c) Stability of expression of VLA-4 by PFSK1 cells. PFSK1 cells from passages 7 to 13 were incubated with either natalizumab at 10 µg/ml or with secondary only control. p -value for comparing binding of natalizumab to secondary only was calculated using unpaired t -test. Variances were compared using F -test. (d) Natalizumab detection in serum from treated patients positive for anti-natalizumab antibodies were compared with anti-natalizumab negative samples ( p < 0.0001, Mann–Whitney test) using an anti-IgG 4 antibody. Each dot corresponds to the binding of IgG 4 on PFSK1 (ratio of GMFI of cells incubated with the sample to cells incubated only with secondary antibody) from each serum sample, tested in three independent experiments.
    Figure Legend Snippet: (a) Natalizumab binding on VLA-4 expressing cells (PFSK1) compared with non-expressing cells (HEK293/T17) by flow cytometry using an FITC-conjugated secondary anti-IgG 4 . (b) Effect of natalizumab blocking antibody HCA250 on natalizumab and milk (T2) IgG 4 binding to PFSK1 cells. Serum was used at 1:40 dilution. Each column corresponds to average binding of IgG 4 on PFSK1 (geometric mean of the florescence intensity – GMFI – of cells incubated with the sample) from three replicates. Error bars are standard error. (c) Stability of expression of VLA-4 by PFSK1 cells. PFSK1 cells from passages 7 to 13 were incubated with either natalizumab at 10 µg/ml or with secondary only control. p -value for comparing binding of natalizumab to secondary only was calculated using unpaired t -test. Variances were compared using F -test. (d) Natalizumab detection in serum from treated patients positive for anti-natalizumab antibodies were compared with anti-natalizumab negative samples ( p < 0.0001, Mann–Whitney test) using an anti-IgG 4 antibody. Each dot corresponds to the binding of IgG 4 on PFSK1 (ratio of GMFI of cells incubated with the sample to cells incubated only with secondary antibody) from each serum sample, tested in three independent experiments.

    Techniques Used: Binding Assay, Expressing, Flow Cytometry, Blocking Assay, Incubation, Control, MANN-WHITNEY



    Similar Products

    pfsk1 cells  (ATCC)
    94
    ATCC pfsk1 cells
    (a) IgG binding on <t>PFSK1</t> cells from CSF of MS donors compared with non-inflammatory controls ( p = 0.008, Mann–Whitney test) using an anti-IgG antibody. Each dot corresponds to the binding of IgG on PFSK1 (ratio of geometric mean of the florescence intensity – GMFI – of cells incubated with the sample to cells incubated only with secondary antibody) from each CSF sample. (b) IgG binding on PFSK1 cells in natalizumab treated compared with untreated patients; results from two independently tested cohorts are pooled and expressed as the number of standard deviations by which each sample is above or below the mean value of the control samples ( p < 0.0001, Mann–Whitney test). Each dot corresponds to one sample. (c) Natalizumab detection in CSF from treated patients compared with untreated patients ( p < 0.0015, Mann–Whitney test) using an anti-IgG 4 antibody. Each dot corresponds to the binding of IgG 4 on PFSK1 (ratio of geometric mean of the florescence intensity – GMFI – of cells incubated with the sample to cells incubated only with secondary antibody) from each serum sample. (d) Natalizumab detection in serum from treated patients compared with untreated patients ( p < 0.0018, Mann–Whitney test) using an anti-IgG 4 antibody. Each dot corresponds to the binding of IgG 4 on PFSK1 (ratio of GMFI of cells incubated with the sample to cells incubated only with secondary antibody) from each serum sample.
    Pfsk1 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pfsk1+cells/pmc09896084-41-0-8?v=ATCC
    Average 94 stars, based on 1 article reviews
    pfsk1 cells - by Bioz Stars, 2026-08
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    (a) IgG binding on PFSK1 cells from CSF of MS donors compared with non-inflammatory controls ( p = 0.008, Mann–Whitney test) using an anti-IgG antibody. Each dot corresponds to the binding of IgG on PFSK1 (ratio of geometric mean of the florescence intensity – GMFI – of cells incubated with the sample to cells incubated only with secondary antibody) from each CSF sample. (b) IgG binding on PFSK1 cells in natalizumab treated compared with untreated patients; results from two independently tested cohorts are pooled and expressed as the number of standard deviations by which each sample is above or below the mean value of the control samples ( p < 0.0001, Mann–Whitney test). Each dot corresponds to one sample. (c) Natalizumab detection in CSF from treated patients compared with untreated patients ( p < 0.0015, Mann–Whitney test) using an anti-IgG 4 antibody. Each dot corresponds to the binding of IgG 4 on PFSK1 (ratio of geometric mean of the florescence intensity – GMFI – of cells incubated with the sample to cells incubated only with secondary antibody) from each serum sample. (d) Natalizumab detection in serum from treated patients compared with untreated patients ( p < 0.0018, Mann–Whitney test) using an anti-IgG 4 antibody. Each dot corresponds to the binding of IgG 4 on PFSK1 (ratio of GMFI of cells incubated with the sample to cells incubated only with secondary antibody) from each serum sample.

    Journal: Therapeutic Advances in Neurological Disorders

    Article Title: Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis

    doi: 10.1177/17562864221150040

    Figure Lengend Snippet: (a) IgG binding on PFSK1 cells from CSF of MS donors compared with non-inflammatory controls ( p = 0.008, Mann–Whitney test) using an anti-IgG antibody. Each dot corresponds to the binding of IgG on PFSK1 (ratio of geometric mean of the florescence intensity – GMFI – of cells incubated with the sample to cells incubated only with secondary antibody) from each CSF sample. (b) IgG binding on PFSK1 cells in natalizumab treated compared with untreated patients; results from two independently tested cohorts are pooled and expressed as the number of standard deviations by which each sample is above or below the mean value of the control samples ( p < 0.0001, Mann–Whitney test). Each dot corresponds to one sample. (c) Natalizumab detection in CSF from treated patients compared with untreated patients ( p < 0.0015, Mann–Whitney test) using an anti-IgG 4 antibody. Each dot corresponds to the binding of IgG 4 on PFSK1 (ratio of geometric mean of the florescence intensity – GMFI – of cells incubated with the sample to cells incubated only with secondary antibody) from each serum sample. (d) Natalizumab detection in serum from treated patients compared with untreated patients ( p < 0.0018, Mann–Whitney test) using an anti-IgG 4 antibody. Each dot corresponds to the binding of IgG 4 on PFSK1 (ratio of GMFI of cells incubated with the sample to cells incubated only with secondary antibody) from each serum sample.

    Article Snippet: PFSK1 cells and HEK293 cells were purchased from ATCC (LGC, Wesel, Germany; CRL-2060 and CRL-11268, respectively).

    Techniques: Binding Assay, MANN-WHITNEY, Incubation, Control

    (a) Natalizumab binding on VLA-4 expressing cells (PFSK1) compared with non-expressing cells (HEK293/T17) by flow cytometry using an FITC-conjugated secondary anti-IgG 4 . (b) Effect of natalizumab blocking antibody HCA250 on natalizumab and milk (T2) IgG 4 binding to PFSK1 cells. Serum was used at 1:40 dilution. Each column corresponds to average binding of IgG 4 on PFSK1 (geometric mean of the florescence intensity – GMFI – of cells incubated with the sample) from three replicates. Error bars are standard error. (c) Stability of expression of VLA-4 by PFSK1 cells. PFSK1 cells from passages 7 to 13 were incubated with either natalizumab at 10 µg/ml or with secondary only control. p -value for comparing binding of natalizumab to secondary only was calculated using unpaired t -test. Variances were compared using F -test. (d) Natalizumab detection in serum from treated patients positive for anti-natalizumab antibodies were compared with anti-natalizumab negative samples ( p < 0.0001, Mann–Whitney test) using an anti-IgG 4 antibody. Each dot corresponds to the binding of IgG 4 on PFSK1 (ratio of GMFI of cells incubated with the sample to cells incubated only with secondary antibody) from each serum sample, tested in three independent experiments.

    Journal: Therapeutic Advances in Neurological Disorders

    Article Title: Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis

    doi: 10.1177/17562864221150040

    Figure Lengend Snippet: (a) Natalizumab binding on VLA-4 expressing cells (PFSK1) compared with non-expressing cells (HEK293/T17) by flow cytometry using an FITC-conjugated secondary anti-IgG 4 . (b) Effect of natalizumab blocking antibody HCA250 on natalizumab and milk (T2) IgG 4 binding to PFSK1 cells. Serum was used at 1:40 dilution. Each column corresponds to average binding of IgG 4 on PFSK1 (geometric mean of the florescence intensity – GMFI – of cells incubated with the sample) from three replicates. Error bars are standard error. (c) Stability of expression of VLA-4 by PFSK1 cells. PFSK1 cells from passages 7 to 13 were incubated with either natalizumab at 10 µg/ml or with secondary only control. p -value for comparing binding of natalizumab to secondary only was calculated using unpaired t -test. Variances were compared using F -test. (d) Natalizumab detection in serum from treated patients positive for anti-natalizumab antibodies were compared with anti-natalizumab negative samples ( p < 0.0001, Mann–Whitney test) using an anti-IgG 4 antibody. Each dot corresponds to the binding of IgG 4 on PFSK1 (ratio of GMFI of cells incubated with the sample to cells incubated only with secondary antibody) from each serum sample, tested in three independent experiments.

    Article Snippet: PFSK1 cells and HEK293 cells were purchased from ATCC (LGC, Wesel, Germany; CRL-2060 and CRL-11268, respectively).

    Techniques: Binding Assay, Expressing, Flow Cytometry, Blocking Assay, Incubation, Control, MANN-WHITNEY